The mechanistic nature of our model enables evaluating the likelihood of the hypothesis of new short-lived CD4 cell infections in a drug-limited compartment explaining the second phase of viral decay.[25] The model consists in the physiological, pharmacological and viral elements interacting to dictate the evolution of the viral population within its host. The gene discussed is CD4; the disease is infection.